中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 6
Jun.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(6): 1068-1074

Survey on the awareness and clinical application of guidelines for the prevention and treatment of chronic hepatitis B （2022 edition） among clinicians

DOI: 10.12449/JCH250611
  • 1.

    Beijing Friendship Hospital，Capital Medical University，Beijing 100050，China

  • 2.

    Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

  • 3.

    Guangzhou Eighth People’s Hospital，Guangzhou Medical University，Guangzhou 510440，China

  • 4.

    The Sixth People’s Hospital of Shenyang，Shenyang 110006，China

  • 5.

    Beijing YouAn Hospital，Capital Medical University，Beijing 100069，China

  • 6.

    The First Affiliated Hospital of Xinjiang Medical University，Urumqi 830054，China

  • 7.

    The First Affiliated Hospital of Wenzhou Medical University，Wenzhou，Zhejiang 325000，China

  • 8.

    Nanjing Second Hospital，Nanjing 211103，China

  • 9.

    Tongji Hospital，Tongji Medical College of Huazhong University of Science and Technology，Wuhan 430030，China

Research funding:

The National Key Research and Development Program, China (2023YFC2306902);

The National Key Research and Development Program, China (2023YFC2306900);

High-level Public Health Technical Talents of the Beijing Municipal Health Commission, China (XUEKEGUGAN-010-018)

More Information
  • Corresponding author: YANG Zhiyun， yangzhiyun66@163.com （ORCID： 0000-0002-1522-0749）; JIA Jidong， jia_jd@ccmu.edu.cn （ORCID： 0000-0002-4673-8890）
  • Published Date: 2025-06-25
    Abstract
  •   Objective  To investigate the awareness and clinical practice of guidelines for the prevention and treatment of chronic hepatitis B （2022 edition） among clinicians.  Methods  From July 19 to December 31， 2024， a self-designed electronic questionnaire was distributed via the WeChat mini program to collect related data from 1 588 clinicians nationwide， including their awareness and practice based on 18 questions regarding testing and referral， diagnosis and treatment， and follow-up.  Results  Among all respondents， only 350 clinicians correctly understood all the updated key points of antiviral indications and treatment for special populations in the 2022 edition of guidelines for the prevention and treatment of chronic hepatitis B， with an overall awareness rate of 22.0%. Only 20% ‍—‍ ‍40% of the patients with positive HBV DNA and an age of >30 years receive antiviral therapy， while 80% ‍—‍ ‍100% of the patients with positive HBV DNA and a family history of hepatitis B cirrhosis or hepatocellular carcinoma receive antiviral therapy. The median follow-up rates at 1 year， 3 years， and 5 years were 67.5% 57.5% and 47.5%，respectively， showing a trend of gradual reduction， which might be associated with the influencing factors such as insufficient time for follow-up management by clinicians， insufficient awareness of the disease among patients， and poor adherence to follow-up.  Conclusion  There is a gap between the awareness and practice of guidelines for the prevention and treatment of chronic hepatitis B （2022 edition） among clinicians. It is recommended to further strengthen training and focus on the whole process of “detection， diagnosis， treatment， and management” for patients with chronic hepatitis B in healthcare institutions， in order to promote the implementation of the guidelines.

     

    • FullText(HTML)
  • loading
    • References(16)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Chin J Infect Dis, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
    [2]
    XIE YD, FENG B, RAO HY. Interpretation of guidelines for the prevention and treatment of chronic hepatitis B(2022 edition)[J]. J Clin Hepatol, 2023, 39( 7): 1553- 1559. DOI: 10.3969/j.issn.1001-5256.2023.07.007.

    谢艳迪, 封波, 饶慧瑛.《慢性乙型肝炎防治指南(2022年版)》解读[J]. 临床肝胆病杂志, 2023, 39( 7): 1553- 1559. DOI: 10.3969/j.issn.1001-5256.2023.07.007.
    [3]
    Web of Science[EB/OL].[ 2025-03-19]. https://jcr.clarivate.com/jcr/search-results. https://jcr.clarivate.com/jcr/search-results
    [4]
    Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35( 12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [5]
    HUANG Y. Age and family history are both not required for initiation of antiviral therapy in patients with chronic hepatitis B[J]. Chin J Hepatol, 2022, 30( 4): 426- 428. DOI: 10.3760/cma.j.cn501113-20220320-00127.

    黄缘. 慢性乙型肝炎患者启动抗病毒治疗: 无需兼备年龄和家族史[J]. 中华肝脏病杂志, 2022, 30( 4): 426- 428. DOI: 10.3760/cma.j.cn501113-20220320-00127.
    [6]
    European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67( 2): 370- 398. DOI: 10.1016/j.jhep.2017.03.021.
    [7]
    TERRAULT NA, LOK ASF, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67( 4): 1560- 1599. DOI: 10.1002/hep.29800.
    [8]
    GANE EJ, CHARLTON MR, MOHAMED R, et al. Asian consensus recommendations on optimizing the diagnosis and initiation of treatment of hepatitis B virus infection in resource-limited settings[J]. J Viral Hepat, 2020, 27( 5): 466- 475. DOI: 10.1111/jvh.13244.
    [9]
    Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan society of hepatology guidelines for the management of hepatitis B virus infection: 2019 update[J]. Hepatol Res, 2020, 50( 8): 892- 923. DOI: 10.1111/hepr.13504.
    [10]
    LUBEL JS, STRASSER SI, THOMPSON AJ, et al. Australian consensus recommendations for the management of hepatitis B[J]. Med J Aust, 2022, 216( 9): 478- 486. DOI: 10.5694/mja2.51430.
    [11]
    REN S, WANG WJ, LU JF, et al. Effect of the change in antiviral therapy indication on identifying significant liver injury among chronic hepatitis B virus infections in the grey zone[J]. Front Immunol, 2022, 13: 1035923. DOI: 10.3389/fimmu.2022.1035923.
    [12]
    CHOI GH, KIM GA, CHOI J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation[J]. Aliment Pharmacol Ther, 2019, 50( 2): 215- 226. DOI: 10.1111/apt.15311.
    [13]
    ZHANG SH, WANG C, LIU B, et al. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: An economic evaluation[J]. Lancet Reg Health West Pac, 2023, 35: 100738. DOI: 10.1016/j.lanwpc.2023.100738.
    [14]
    SHAN S, ZHAO XY, JIA JD. Comprehensive approach to controlling chronic hepatitis B in China[J]. Clin Mol Hepatol, 2024, 30( 2): 135- 143. DOI: 10.3350/cmh.2023.0412.
    [15]
    School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College; School of Public Health, Peking University; Department of Management on Infectious Diseases, Chinese Center for Disease Control and Prevention, et al. Expert consensus on the key technologies for a multi‑point trigger intelligent surveillance and early warning system for infectious diseases[J]. Natl Med J China, 2024, 104( 32): 2995- 3009. DOI: 10.3760/cma.j.cn112137-20240612-01317.

    中国医学科学院北京协和医学院群医学及公共卫生学院, 北京大学公共卫生学院, 中国疾病预防控制中心传染病管理处, 等. 传染病多点触发智慧化监测预警系统关键技术专家共识[J]. 中华医学杂志, 2024, 104( 32): 2995- 3009. DOI: 10.3760/cma.j.cn112137-20240612-01317.
    [16]
    Notice on issuing the National Disease Prevention and Control Action Plan( 2024-2025)[EB/OL].( 2024-05-29)[ 2025-03-19]. https://www.ndcpa.gov.cn/jbkzzx/c100014/common/content/content_17957038340-32320512.html. https://www.ndcpa.gov.cn/jbkzzx/c100014/common/content/content_1795703834032320512.html

    关于印发全国疾病预防控制行动方案( 2024— 2025 年) 的通知[EB/OL].( 2024-05-29)[ 2025-03-19]. https://www.ndcpa.gov.cn/jbkzzx/c100014/common/content/content_1795703834032320512.html. https://www.ndcpa.gov.cn/jbkzzx/c100014/common/content/content_1795703834032320512.html
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (589) PDF downloads(65) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return